AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 232 min read$ACIU

AC Immune Posts Positive Week 100 Phase 2 Data For ACI-7104 In Parkinson's Disease; Stock Up

AC Immune SA (ACIU) reported positive Week-100 results from its Phase 2 VacSYn trial for ACI-7104, a vaccine candidate for Parkinson's disease. The treatment met all primary endpoints, showing safety, tolerability, and strong immune response. The stock rose 2.82% to $2.73 on Tuesday and is up 7.65% in pre-market trading.

Original reporting
rttnews.com
Published Sep 23, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ACIU
Bullish
high confidence
Mentioned
$ACIU
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ACIUBullishMed
01

Why it matters

Positive Phase 2 results could accelerate regulatory discussions and attract partnership interest.

02

Market read

First report of positive trial data; likely to move ACIU stock and affect related neuro‑degenerative biotech stocks.

03

What to watch

Small sample size (34 patients) and lack of clinical outcome data limit confidence.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

AC Immune SA is a Swiss biotech developing immunotherapies for neuro‑degenerative diseases.

Company-level read

Ticker impact

$ACIUBullishHigh confidence
Context

Positive Week-100 Phase 2 data for ACI-7104 in Parkinson's disease reported.

Expected impact

Potential upside as investors price in future Phase 3 prospects.

Evidence & confidence

First disclosure of positive data for a biotech candidate typically lifts valuation, especially with FDA discussions slated for early 2027.

Market effects

Sector

Boosts sentiment for neuro‑degenerative disease immunotherapy sector.

Regional

Positive for European biotech listings, especially Swiss‑based firms.

Global

May influence global biotech investors tracking Parkinson's disease pipelines.

Counterpoint

What could challenge this read

Data are early‑stage; efficacy not proven, risk of later‑stage failure remains.

Key entities

  • company
    AC Immune SA

    Swiss biotech developing ACI-7104 vaccine candidate.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 24
$ACIUMedAI 8/10

AC Immune says ACI-7104 shows durable immunogenicity

AC Immune (ACIU) reported positive safety and immunogenicity results for ACI-7104 in a Phase II trial for Parkinson's disease. The study's Part 1 involved 34 patients, with 25 receiving ACI-7104. Shares rose 3.7% to $2.83 on the news. The trial aims to assess safety, tolerability, and immunogenicity in Part 1, and clinical activity in Part 2.

thepharmaletter.com1 min
SEP 23
$ACIUHighAI 9/10

AC Immune reports positive phase 2 trial results for ACI-7104

AC Immune (ACIU) reported positive phase 2 trial results for ACI-7104 in early-stage Parkinson’s disease. All 25 patients developed antibodies, with the treatment being safe and well-tolerated. The trial continues with a two-year extension and plans for Part 2. ACI-7104 targets alpha-synuclein protein aggregates, and the company has partnerships worth $4.5B in potential milestones.

investing.com2 min
AUG 20
$ACIUMedAI 8/10

AC Immune stock gains on early Phase 1 trial results

AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.

investing.com2 min